These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36921274)

  • 21. Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case-control study, United Kingdom, 2022.
    Chatzilena A; Hyams C; Challen R; Marlow R; King J; Adegbite D; Kinney J; Clout M; Maskell N; Oliver J; Finn A; Danon L;
    Euro Surveill; 2023 Nov; 28(48):. PubMed ID: 38037728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.
    Klein NP; Stockwell MS; Demarco M; Gaglani M; Kharbanda AB; Irving SA; Rao S; Grannis SJ; Dascomb K; Murthy K; Rowley EA; Dalton AF; DeSilva MB; Dixon BE; Natarajan K; Stenehjem E; Naleway AL; Lewis N; Ong TC; Patel P; Konatham D; Embi PJ; Reese SE; Han J; Grisel N; Goddard K; Barron MA; Dickerson M; Liao IC; Fadel WF; Yang DH; Arndorfer J; Fireman B; Griggs EP; Valvi NR; Hallowell C; Zerbo O; Reynolds S; Ferdinands J; Wondimu MH; Williams J; Bozio CH; Link-Gelles R; Azziz-Baumgartner E; Schrag SJ; Thompson MG; Verani JR
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):352-358. PubMed ID: 35239634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022.
    McConeghy KW; White EM; Blackman C; Santostefano CM; Lee Y; Rudolph JL; Canaday D; Zullo AR; Jernigan JA; Pilishvili T; Mor V; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(39):1235-1238. PubMed ID: 36173757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
    Arbel R; Peretz A; Sergienko R; Friger M; Beckenstein T; Duskin-Bitan H; Yaron S; Hammerman A; Bilenko N; Netzer D
    Lancet Infect Dis; 2023 Aug; 23(8):914-921. PubMed ID: 37062302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
    Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
    Mateo-Urdiales A; Sacco C; Fotakis EA; Del Manso M; Bella A; Riccardo F; Bressi M; Rota MC; Petrone D; Siddu A; Fedele G; Stefanelli P; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M
    Lancet Infect Dis; 2023 Dec; 23(12):1349-1359. PubMed ID: 37478877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States.
    Tseng HF; Ackerson BK; Sy LS; Tubert JE; Luo Y; Qiu S; Lee GS; Bruxvoort KJ; Ku JH; Florea A; Takhar HS; Bathala R; Zhou CK; Esposito DB; Marks MA; Anderson EJ; Talarico CA; Qian L
    Nat Commun; 2023 Sep; 14(1):5851. PubMed ID: 37730701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.
    Kirsebom FCM; Andrews N; Stowe J; Ramsay M; Lopez Bernal J
    Lancet Infect Dis; 2023 Nov; 23(11):1235-1243. PubMed ID: 37453440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
    Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
    Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States.
    Schrag SJ; Verani JR; Dixon BE; Page JM; Butterfield KA; Gaglani M; Vazquez-Benitez G; Zerbo O; Natarajan K; Ong TC; Lazariu V; Rao S; Beaver R; Ellington SR; Klein NP; Irving SA; Grannis SJ; Kiduko S; Barron MA; Midturi J; Dickerson M; Lewis N; Stockwell MS; Stenehjem E; Fadel WF; Link-Gelles R; Murthy K; Goddard K; Grisel N; Valvi NR; Fireman B; Arndorfer J; Konatham D; Ball S; Thompson MG; Naleway AL
    JAMA Netw Open; 2022 Sep; 5(9):e2233273. PubMed ID: 36156146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3-5 Years - Increasing Community Access to Testing Program, United States, July 2022-February 2023.
    Fleming-Dutra KE; Ciesla AA; Roper LE; Smith ZR; Miller JD; Accorsi EK; Verani JR; Shang N; Derado G; Wiegand RE; Pilishvili T; Britton A; Link-Gelles R
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(7):177-182. PubMed ID: 36795625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents - United States, 2021-2023.
    Zambrano LD; Newhams MM; Simeone RM; Payne AB; Wu M; Orzel-Lockwood AO; Halasa NB; Calixte JM; Pannaraj PS; Mongkolrattanothai K; Boom JA; Sahni LC; Kamidani S; Chiotos K; Cameron MA; Maddux AB; Irby K; Schuster JE; Mack EH; Biggs A; Coates BM; Michelson KN; Bline KE; Nofziger RA; Crandall H; Hobbs CV; Gertz SJ; Heidemann SM; Bradford TT; Walker TC; Schwartz SP; Staat MA; Bhumbra SS; Hume JR; Kong M; Stockwell MS; Connors TJ; Cullimore ML; Flori HR; Levy ER; Cvijanovich NZ; Zinter MS; Maamari M; Bowens C; Zerr DM; Guzman-Cottrill JA; Gonzalez I; Campbell AP; Randolph AG;
    MMWR Morb Mortal Wkly Rep; 2024 Apr; 73(15):330-338. PubMed ID: 38635481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages.
    Ackerson BK; Bruxvoort KJ; Qian L; Sy LS; Qiu S; Tubert JE; Lee GS; Ku JH; Florea A; Luo Y; Bathala R; Stern J; Choi SK; Takhar HS; Aragones M; Marks MA; Anderson EJ; Zhou CK; Sun T; Talarico CA; Tseng HF
    Hum Vaccin Immunother; 2024 Dec; 20(1):2335052. PubMed ID: 38575149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Wang LF; Ren EC; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Dec; 23(12):1343-1348. PubMed ID: 37543042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 Bivalent Booster Vaccination Coverage and Intent to Receive Booster Vaccination Among Adolescents and Adults - United States, November-December 2022.
    Lu PJ; Zhou T; Santibanez TA; Jain A; Black CL; Srivastav A; Hung MC; Kriss JL; Schorpp S; Yankey D; Sterrett N; Fast HE; Razzaghi H; Elam-Evans LD; Singleton JA
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(7):190-198. PubMed ID: 36795677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
    Plumb ID; Briggs Hagen M; Wiegand R; Dumyati G; Myers C; Harland KK; Krishnadasan A; James Gist J; Abedi G; Fleming-Dutra KE; Chea N; Lee JE; Kellogg M; Edmundson A; Britton A; Wilson LE; Lovett SA; Ocampo V; Markus TM; Smithline HA; Hou PC; Lee LC; Mower W; Rwamwejo F; Steele MT; Lim SC; Schrading WA; Chinnock B; Beiser DG; Faine B; Haran JP; Nandi U; Chipman AK; LoVecchio F; Eucker S; Femling J; Fuller M; Rothman RE; Curlin ME; Talan DA; Mohr NM;
    Vaccine; 2024 Apr; 42(10):2543-2552. PubMed ID: 37973512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
    Maeda H; Saito N; Igarashi A; Ishida M; Terada M; Masuda S; Osawa R; Hosokawa N; Nakashima K; Kamura H; Imura H; Inoue H; Matsuzaka S; Sugimoto Y; Kuwamitsu O; Motohashi I; Morikawa T; Oda R; Hoshina Y; Matono T; Teshigahara O; Sando E; Asami S; Kudo S; Akizuki N; Muto Y; Hayakawa T; Kishaba T; Ohara Y; Kubo Y; Suzuki M; Morimoto K
    Expert Rev Vaccines; 2024; 23(1):213-225. PubMed ID: 38288980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.
    Song S; Madewell ZJ; Liu M; Miao Y; Xiang S; Huo Y; Sarkar S; Chowdhury A; Longini IM; Yang Y
    Vaccine; 2024 May; 42(15):3389-3396. PubMed ID: 38653679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024.
    DeCuir J; Payne AB; Self WH; Rowley EAK; Dascomb K; DeSilva MB; Irving SA; Grannis SJ; Ong TC; Klein NP; Weber ZA; Reese SE; Ball SW; Barron MA; Naleway AL; Dixon BE; Essien I; Bride D; Natarajan K; Fireman B; Shah AB; Okwuazi E; Wiegand R; Zhu Y; Lauring AS; Martin ET; Gaglani M; Peltan ID; Brown SM; Ginde AA; Mohr NM; Gibbs KW; Hager DN; Prekker M; Mohamed A; Srinivasan V; Steingrub JS; Khan A; Busse LW; Duggal A; Wilson JG; Chang SY; Mallow C; Kwon JH; Exline MC; Columbus C; Vaughn IA; Safdar B; Mosier JM; Harris ES; Casey JD; Chappell JD; Grijalva CG; Swan SA; Johnson C; Lewis NM; Ellington S; Adams K; Tenforde MW; Paden CR; Dawood FS; Fleming-Dutra KE; Surie D; Link-Gelles R;
    MMWR Morb Mortal Wkly Rep; 2024 Feb; 73(8):180-188. PubMed ID: 38421945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021.
    Embi PJ; Levy ME; Patel P; DeSilva MB; Gaglani M; Dascomb K; Dunne MM; Klein NP; Ong TC; Grannis SJ; Natarajan K; Yang DH; Stenehjem E; Zerbo O; McEvoy C; Rao S; Thompson MG; Konatham D; Irving SA; Dixon BE; Han J; Schrader KE; Grisel N; Lewis N; Kharbanda AB; Barron MA; Reynolds S; Liao IC; Fadel WF; Rowley EA; Arndorfer J; Goddard K; Murthy K; Valvi NR; Weber ZA; Fireman B; Reese SE; Ball SW; Naleway AL
    Vaccine; 2023 Aug; 41(37):5424-5434. PubMed ID: 37479609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.